conducted a study investigating the impact of systemic SCFAs, particularly butyrate and propionate, on the therapeutic outcomes of Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) immune checkpoint inhibitor treatment in both murine models and individuals with advanced cancer (79). The gene discussed is CTLA4; the disease is cancer.